Αναζήτηση Δραστικών

PEGVISOMANT

ATC

Εμπορικές Ονομασίες

  • SOMAVERT
    Μορφές: PS.INJ.SOL
    Μορφές:
  • DRUGBANK - Pegvisomant
  • indication:

    Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.

  • pharmacology:

  • mechanism:

    Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.

  • toxicity:

  • absorprion:

  • halflife:

    ~6 days

  • roouteelimination:

  • volumedistribution:

    * 7 L

  • clearance:

    * 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]